Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J McCleary

Showing results (61-70 of 82) with videos related to

Pageof 9
Sort By:
JCO Clinical Cancer Informatics|October 3, 2023
Feasibility of Weekly Electronic Health Record-Embedded Patient-Reported Outcomes for Patients Starting Oral Cancer-Directed TherapyJim W Doolin, Ellana K Haakenstad, Bridget A Neville, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 23, 2015
Prognostic Utility of Molecular Factors by Age at Diagnosis of Colorectal CancerNadine J McCleary, Kaori Sato, Reiko Nishihara, et al.
Critical Care Medicine|May 5, 2018
Insidious Harm of Medication Diluents as a Contributor to Cumulative Volume and Hyperchloremia: A Prospective, Open-Label, Sequential Period Pilot StudyCarolyn A Magee, Melissa L Thompson Bastin, Melanie E Laine, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 8, 2011
Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803Shuji Ogino, Kaori Shima, Jeffrey A Meyerhardt, et al.
The Oncologist|January 21, 2025
A phase II study of ramucirumab and somatostatin analog therapy in patients with advanced neuroendocrine tumorsKimberly Perez, Matthew H Kulke, Hui Zheng, et al.
The Oncologist|May 14, 2014
Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinomaBrian M Wolpin, Douglas A Rubinson, Xiaoxu Wang, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 18, 2022
Adoption of Patient-Generated Health Data in Oncology: A Report From the NCCN EHR Oncology Advisory GroupPeter D Stetson, Nadine J McCleary, Travis Osterman, et al.
Journal of the National Cancer Institute|November 16, 2013
Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trialShuji Ogino, Xiaoyun Liao, Yu Imamura, et al.
The Oncologist|April 13, 2013
Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancerBrian M Wolpin, Kimmie Ng, Andrew X Zhu, et al.
Practical Radiation Oncology|June 4, 2014
Delaying chemoradiation until after completion of adjuvant chemotherapy for pancreatic cancer may not impact local controlJennifer Y Wo, Stephanie K Childs, Jackie Szymonifka, et al.
Pageof 9

Showing results (61-70 of 82) with videos related to

Sort By:
Pageof 9
JCO Clinical Cancer Informatics|October 3, 2023
Feasibility of Weekly Electronic Health Record-Embedded Patient-Reported Outcomes for Patients Starting Oral Cancer-Directed TherapyJim W Doolin, Ellana K Haakenstad, Bridget A Neville, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 23, 2015
Prognostic Utility of Molecular Factors by Age at Diagnosis of Colorectal CancerNadine J McCleary, Kaori Sato, Reiko Nishihara, et al.
Critical Care Medicine|May 5, 2018
Insidious Harm of Medication Diluents as a Contributor to Cumulative Volume and Hyperchloremia: A Prospective, Open-Label, Sequential Period Pilot StudyCarolyn A Magee, Melissa L Thompson Bastin, Melanie E Laine, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 8, 2011
Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803Shuji Ogino, Kaori Shima, Jeffrey A Meyerhardt, et al.
The Oncologist|January 21, 2025
A phase II study of ramucirumab and somatostatin analog therapy in patients with advanced neuroendocrine tumorsKimberly Perez, Matthew H Kulke, Hui Zheng, et al.
The Oncologist|May 14, 2014
Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinomaBrian M Wolpin, Douglas A Rubinson, Xiaoxu Wang, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 18, 2022
Adoption of Patient-Generated Health Data in Oncology: A Report From the NCCN EHR Oncology Advisory GroupPeter D Stetson, Nadine J McCleary, Travis Osterman, et al.
Journal of the National Cancer Institute|November 16, 2013
Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trialShuji Ogino, Xiaoyun Liao, Yu Imamura, et al.
The Oncologist|April 13, 2013
Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancerBrian M Wolpin, Kimmie Ng, Andrew X Zhu, et al.
Practical Radiation Oncology|June 4, 2014
Delaying chemoradiation until after completion of adjuvant chemotherapy for pancreatic cancer may not impact local controlJennifer Y Wo, Stephanie K Childs, Jackie Szymonifka, et al.
Pageof 9